Fulltext

Stem cell therapies for myocardial infarction in clinical trials: bioengineering and biomaterial aspects

Higuchi A 1 , Ku NJ 1 , Tseng YC 1 , Pan CH 1 , Li HF 1 , Kumar SS 2 Show all authors , Ling QD 3 , Chang Y 4 , Alarfaj AA 5 , Munusamy MA 5 , Benelli G 6 , Murugan K 7

Affiliations 

  • 1 Department of Chemical and Materials Engineering, National Central University, Jhongli, Taoyuan, Taiwan
  • 2 Department of Medical Microbiology and Parasitology, Universiti Putra Malaysia, Serdang, Selangor, Malaysia
  • 3 Cathay Medical Research Institute, Cathay General Hospital, Hsi-Chi City, Taipei, Taiwan
  • 4 Department of Chemical Engineering, R&D Center for Membrane Technology, Chung Yuan Christian University, Chungli, Taoyuan, Taiwan
  • 5 Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia
  • 6 Department of Agriculture, Food and Environment, University of Pisa, Via del Borghetto, Pisa, Italy
  • 7 Division of Entomology, Department of Zoology, School of Life Sciences, Bharathiar University, Coimbatore, Tamil Nadu, India
Lab Invest, 2017 Oct;97(10):1167-1179.
PMID: 28869589 DOI: 10.1038/labinvest.2017.100

Abstract

Cardiovascular disease remains the leading cause of death and disability in advanced countries. Stem cell transplantation has emerged as a promising therapeutic strategy for acute and chronic ischemic cardiomyopathy. The current status of stem cell therapies for patients with myocardial infarction is discussed from a bioengineering and biomaterial perspective in this review. We describe (a) the current status of clinical trials of human pluripotent stem cells (hPSCs) compared with clinical trials of human adult or fetal stem cells, (b) the gap between fundamental research and application of human stem cells, (c) the use of biomaterials in clinical and pre-clinical studies of stem cells, and finally (d) trends in bioengineering to promote stem cell therapies for patients with myocardial infarction. We explain why the number of clinical trials using hPSCs is so limited compared with clinical trials using human adult and fetal stem cells such as bone marrow-derived stem cells.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications